Unbiased Analysis of Today's Healthcare Issues
In the past, I have written about the Enhancing Oncology Model (EOM), including an overview of the EOM program as well as a more detailed review of EOM’s payment methodology. A new paper in JAMA Health Forum by Kocher and Adashi (2023) describes their perspective on the EOM program. First, they provide a nice overview…
AI and healthcare spending. Referral incentives for TB screening. A better measure of population density. IVI: “No value without equity” Medicaid’s multi-generational health benefit. How do people use ‘work from home’ time savings?
Based on a study by Frankovic and Kuhn (2022), the answer is both. However, the value of increased innovation–as measured through longevity gains–more than offset inefficiencies from overspending. Specifically, the authors use an overlapping generations model where individuals can purchase health insurance and medical progress depends on health care sector return on investment. The authors…
Paid family leave (PFL) provide paid time off for workers who care for a newborn (parental leave) or care for a sick or temporarily disabled family member (caregiving leave). The US is one of the few countries that does not offer PFL, but a number of State have decided to adopt their own policy. California…
The year 2022 was a good, but perhaps not great year for innovation. According to the FDA’s Center for Drug Evaluation and Research’s (CDER) New Drug Therapy Approvals 2022 report, there were 37 novel drugs approved in 2022. This number is down from the historical rate of approvals between 2013-2021 (43.4 approvals per year) and…
“More is lost by indecision than wrong decision. Indecision is the thief of opportunity. It will steal you blind.” — Cicero
Nobody in this world can tell me what to think, but I think everybody has a lesson to teach me. Lex Fridman.
HESG Winter 2023. Use AI to search books…with source material! Is ChatGPT left or right-wing? Dr. Smartphone. UK ‘Netflix’ payment model for antibacterials. Managed Care Year-End Recap.
The primary reasons is that it is much faster and less expensive to repurpose an existing drug for a new disease than trying to identify a new therapeutic agent. A paper by Islam et al. (2021) explains why: Available information. A repurposed drug has an extensive portfolio of knowledge relating to human pharmacokinetics, bioavailability and…
That is the takeaway according to a November-December 2022 survey by PhRMA of 25 large pharmaceutical manufacturers. Among respondents, it was clear the IRA price setting provisions are already impacting, and are expected to have a growing impact on, R&D plans moving forward:• 78% expect to cancel early-state pipeline projects.• 63% said they expect to…